Royal Bank of Canada
VKTX icon

Royal Bank of Canada’s Viking Therapeutics VKTX Stock Holding History

Royal Bank of Canada’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$5.3M – 7498
2024
Q2 		$5.3M Buy
+100,000
New +$6.56M ﹤0.01% 2133
2019
Q3 		– Sell
-400
Closed -$3K – 7155
2019
Q2 		$3K Buy
+400
New +$3.42K ﹤0.01% 6501

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Royal Bank of Canada's VKTX Position: Q2 2026 in Review

Royal Bank of Canada reduced its Viking Therapeutics (VKTX) stake by 39% in Q2 2026, selling an estimated $5.07M and leaving 241,032 shares worth $9.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Royal Bank of Canada first reported a position in VKTX in Q4 2015 and has held it in 37 quarters since. The position peaked at $25.1M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Royal Bank of Canada held 241,032 shares of Viking Therapeutics worth $9.4M as of Q2 2026.
  • Royal Bank of Canada sold 156,936 Viking Therapeutics shares in Q2 2026, an estimated $5.07M.
  • Viking Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2134 holding.
  • Royal Bank of Canada first reported a position in Viking Therapeutics in Q4 2015 and has held it in 37 quarters since.
  • Royal Bank of Canada's Viking Therapeutics position peaked at $25.1M in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.